[Antibacterial effectiveness of long-acting isoniazid in the experiment].
The therapeutical efficiency of the long-acting lysosomotropic, complex drug isoniazid (LALCI) was tested in vivo and its antibacterial activity was studied in vitro. LALCI treatment of mice inoculated by virulent Mycobacterium tuberculosis was found to increase their life by 33% as compared with isoniazid. The findings suggest that the higher antibacterial effect of LALCI was due to the dextran matrix that potentiates the antibacterial activity of macrophages by acting on phagosomal and lysosomal cohesion.